Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06313346
Other study ID # 2023.200
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 8, 2024
Est. completion date June 15, 2024

Study information

Verified date December 2023
Source Clinica Universidad de Navarra, Universidad de Navarra
Contact Fermín I Milagro Yoldi, PhD
Phone +34948425600
Email fmilagro@unav.es
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this randomized clinical trial is to learn about the effect of consuming a probiotic on the microbiota associated with immune health and inflammation in healthy women and men after 6 weeks of intervention. The main questions to answer are: 1. To study changes in the intestinal microbiota associated with immune health and inflammation related to probiotic intake. 2. To evaluate changes in salivary cortisol after ingestion of the probiotic. 3. To compile the number and intensity of catarrhal episodes suffered by the participants along the study. For this purpose, a randomized, double blind parallel study has been designed. Target sample size is 60 subjects. Participants will be allocated in two groups for 6 weeks: - Experimental group (n=30): daily consumption of one probiotic capsule. - Placebo group (n=30): daily consumption of one placebo capsule.


Description:

Volunteers who wish to participate in the study will be interviewed by phone to verify that they meet the main inclusion criteria. Volunteers who meet the main inclusion criteria will be invited to an information and screening visit to resolve any doubts. Volunteers who agree to participate in the study will sign the informed consent and will be randomly allocated to one of the two arms of the study and will be provided with any required material. During the intervention, volunteers will attend two Clinical investigation visits. The first one will be carried out on the first day of the study and the last one will take place at the end of the 6 weeks. In both visits anthropometric and body composition measurements, stool and saliva samples, as well as data about dietary, physical activity and catarrhal episodes will be taken.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date June 15, 2024
Est. primary completion date April 24, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 65 Years
Eligibility Inclusion Criteria: - Volunteers of both sexes. - Age between 40 and 65 years old. - Volunteers with a body mass index between 18.5 and 30 kg/m2. - Subjects have to present a stable weight (+/- 3 kg) in the last three months prior to the start of the study. - Subjects must be able to understand and be willing to sign the informed consent, and comply with all study procedures and requirements. Exclusion Criteria: - Subjects with relevant functional or structural anomalies of the digestive system, such as malformations, angiodysplasias, active peptic ulcers, chronic inflammatory or malabsorption diseases, hiatal hernia, reflux, etc. - Subjects with surgical interventions with permanent consequences in the digestive system (for example, gastroduodenostomy). - Subjects following treatments that alter gastrointestinal function, either chronically or occasionally. - Subjects who are being treated with antibiotics (in order to participate, they do not have to have taken antibiotics during the two months prior to the baseline visit). - Subjects with any type of cancer or undergoing treatment for it, or less than 5 years since its eradication. - Subjects with any liver disease (may participate with non-alcoholic fatty liver disease). - Subjects with allergy to any component of the product under study. - Subjects with a high alcohol intake, more than 14 units (women)/day and 20 units (men)/day. - Women who are breastfeeding or pregnant. - Subjects who present some type of cognitive and/or psychological impairment. - Subjects with poor collaboration or with difficulties for following the study procedures. - Subjects who work with shift changes that include nights. - Subjects who follow any type of supplementation that interferes with the study (example: consumption of probiotics). - Subjects who are immersed in diet/exercise changes.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Probiotic
Probiotic capsules
Placebo
Placebo capsules

Locations

Country Name City State
Spain Centre for Nutrition Research Pamplona Navarre

Sponsors (1)

Lead Sponsor Collaborator
Clinica Universidad de Navarra, Universidad de Navarra

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fecal microbiota Fecal microbiota of participants will be analyzed by bacterial 16S gene sequencing technology. Clinical Investigation Day 1 and Clinical Investigation Day 2
Secondary Salivary cortisol Cortisol levels will be taken by SalivetteĀ®- Cortisol kit and analyzed by electrochemiluminescence immunoassay and reported in ug/dL. Clinical Investigation Day 1 (at wake up in the morning) and Clinical Investigation Day 2 (at wake up in the morning, at the same time taken in the clinical investigation day 1)]
Secondary Body weight Weight of participants will be measured by bioimpedance and reported in kg Clinical Investigation Day 1 and Clinical Investigation Day 2
Secondary Height Height of participants will be measured by stadiometer and reported in m. Clinical Investigation Day 1.
Secondary Body mass index Body mass index will be calculated as follows: weight (kilograms)/ height (cm)2. Clinical Investigation Day 1 and Clinical Investigation Day 2.
Secondary Body fat percentage Body fat of participants will be analyzed by bioimpedance and reported in percentage and kilograms. Clinical Investigation Day 1 and Clinical Investigation Day 2.
Secondary Body muscle mass Body muscle mass of participants will be analyzed by bioimpedance and reported in kilograms. Clinical Investigation Day 1 and Clinical Investigation Day 2.
Secondary Body lean mass Body leen mass of participants will be analyzed by bioimpedance and reported in kilograms. Clinical Investigation Day 1 and Clinical Investigation Day 2.
Secondary Body water mass Body water mass of participants will be analyzed by bioimpedance and reported in kilograms. Clinical Investigation Day 1 and Clinical Investigation Day 2.
Secondary Body bone mass Body bone mass of participants will be analyzed by bioimpedance and reported in kilograms. Clinical Investigation Day 1 and Clinical Investigation Day 2.
Secondary The incidence of catarrhal episodes The number of catarrhal episodes will be registrated through a questionnaire designed for that purpose. Clinical Investigation Day 1 and Clinical Investigation Day 2.
Secondary The gravity of catarrhal episodes The gravity (mild/half /serious) of catarrhal episodes will be registrated through a questionnaire designed for that purpose. Clinical Investigation Day 1 and Clinical Investigation Day 2.
Secondary Gastrointestinal symptoms Gastrointestinal symptoms will be registrated through Gastrointestinal Symptoms Rating Scale questionnaire, which is a questionnaire of 15 items. The questionnaire has a seven-point graded likert-type scale, where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms. Clinical Investigation Day 1 and Clinical Investigation Day 2.
Secondary Dietary intake Dietary intake (energy, macronutrients and micronutrients) will be analysed by food frequency questionnaire. Clinical Investigation Day 1 and Clinical Investigation Day 2.
Secondary Physical activity Physical activity will be evaluated by the reduced version of the International Physical Activity Questionnaire, which estimates the total physical activity in MET-min/week, time spent sitting and classifies subjects based on their physical activity Clinical Investigation Day 1 and Clinical Investigation Day 2.
Secondary Adherence to capsule consumption Adherence will be assessed using the capsule consumption record form. Clinical Investigation Day 1 and Clinical Investigation Day 2.
See also
  Status Clinical Trial Phase
Withdrawn NCT03239197 - Project SHARE (motherS Have All the Right microbEs) N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Recruiting NCT06144905 - Norwegian Microbiota Study in Anorexia Nervosa
Completed NCT05864352 - The Role of Dietary Titanium Dioxide on the Human Gut Microbiome and Health
Recruiting NCT04138979 - Intestinal Microbiota of Breast Cancer Patients Undergoing Chemotherapy
Recruiting NCT04132713 - Study on Skin Microbiome of HFS
Completed NCT05726435 - Effects of Soluble Dietary Fiber on Sport Efficiency and Fatigue Delay in Top Basketball Players N/A
Recruiting NCT02695784 - Probiotics After Discharge Phase 4
Completed NCT03543891 - Intestinal Microbiota and Thyroid Cancer
Completed NCT05242913 - Effects of Resistant Potato Starch on the Gut Microbiota N/A
Recruiting NCT04200521 - The Effect of Bariatric Procedures on Gut Microbiota in Obese Individuals in United Arab Emirates and Lebanon
Recruiting NCT05891977 - Effect of Tomato Paste Consumption on the Microbiota-gut-brain Axis in Healthy Adults N/A
Completed NCT02988349 - Ecological Effect of Arginine Dentifrice on Oral Microbiota N/A
Completed NCT05352724 - Clinical Trial to Evaluate the Efficacy of a Sport Drink After High-intensity Aerobic Exercise N/A
Completed NCT04674839 - The Impact of MS-20 on Gut Microbiota Composition in Adult Individuals N/A
Completed NCT03754504 - Effects of Cranberry Powder Supplements on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT05394948 - Circular Economy and the Design of Healthy and Sustainable Food and Ingredients N/A
Terminated NCT03752372 - Microbiome Alterations in IL10RA-deficient Patients After HSCT
Completed NCT05974124 - Effectiveness of Ophthalmic Antiseptic Preparations N/A
Recruiting NCT02005003 - Cognitive and Metabolic Effects of a Probiotic Supplement N/A